quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:04:08·86d
INSIDERFiling
Larimar Therapeutics Inc. logo

President and CEO Ben-Maimon Carole was granted 100,100 shares, increasing direct ownership by 37% to 368,276 units (SEC Form 4)

LRMR· Larimar Therapeutics Inc.
Health Care
Original source

Companies

  • LRMR
    Larimar Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 29UpdateTruist$18.00
  • Oct 16UpdateOppenheimer$26.00
  • Oct 3UpdateWedbush$22.00
  • Oct 2UpdateH.C. Wainwright$15.00
  • Sep 4UpdateRobert W. Baird$16.00
  • Apr 3UpdateLeerink Partners$25.00

Related

  • SEC3d
    SEC Form DEF 14A filed by Larimar Therapeutics Inc.
  • SEC13d
    SEC Form PRE 14A filed by Larimar Therapeutics Inc.
  • SEC35d
    SEC Form S-8 filed by Larimar Therapeutics Inc.
  • SEC35d
    SEC Form 10-K filed by Larimar Therapeutics Inc.
  • SEC36d
    Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR36d
    Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
  • SEC45d
    Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR50d
    Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022